First half financial year 2022 results

Solid results from CSL today. The market approves and has pushed up the share price 8% at the time of writing.

A 5.3% increase in revenue to just over US$6 billion. Management says the measures to deal with plasma collection "will underpin stronger Ig and albumin sales going forward". Guidance has been upgraded.

https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02487088-3A587334?access_token=83ff96335c2d45a094df02a206a39ff4